Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Allarity Therapeutics, Inc. (ALLR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1000-0.0600 (-5.17%)
At close: 04:00PM EDT
1.1000 0.00 (0.00%)
After hours: 04:49PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close1.1600
Open1.1100
Bid1.0900 x 1400
Ask1.1500 x 800
Day's Range1.1000 - 1.1500
52 Week Range1.0100 - 18.2000
Volume32,990
Avg. Volume306,915
Market Cap11.286M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALLR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allarity Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermInterest rates across the entire curve went somewhat parabolic in August. The U.S. Dollar Index continued its very steep ascent. The Federal Reserve is maintaining its hawkish stance based on its latest fed funds targets. As well, the Fed "finally" is getting its quantitative tightening (QT) in gear, which pulls liquidity out of the marketplace. Oh, and stock investors have been losing massive amounts of money. One might believe the economy is falling off a cliff. At least gasoline prices have crashed.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors

    Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022. Mr. McLaughlin is a highly accomplished biotechnology executive with extensive exp

  • GlobeNewswire

    Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference

    Press release Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, announced that Chief Executive Officer James G. Cullem will deliver a corporate update and host investor 1x1 meetings at the Ladenburg Thalmann Healthcare Conference in New York, NY. Mr. Cullem’s presenta

  • Zacks Small Cap Research

    ALLR: A Precision Undertaking

    By John Vandermosten, CFA NASDAQ:ALLR READ THE FULL ALLR RESEARCH REPORT INITIATING COVERAGE We are initiating coverage of Allarity Therapeutics, Inc., (NASDAQ:ALLR) with a valuation of $5.00 per share. Allarity has developed its Drug Response Predictor (DRP ® ) platform, which enables the creation of a drug-specific companion diagnostic to identify cancer patients that will most likely respond

Advertisement
Advertisement